

Bruno Jose DumÃ^{at} Fernandes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4460410/publications.pdf>

Version: 2024-02-01

10
papers

115
citations

1683354

5
h-index

1473754

9
g-index

10
all docs

10
docs citations

10
times ranked

161
citing authors

#	ARTICLE	IF	CITATIONS
1	Low Doses Naltrexone: The Potential Benefit Effects for its Use in Patients with Cancer. <i>Current Drug Research Reviews</i> , 2021, 13, 86-89.	0.7	4
2	Toxicological alert: Exposure to glycidyl methacrylate and cancer risk. <i>Toxicology and Industrial Health</i> , 2020, 36, 937-939.	0.6	5
3	Should the Vancomycin Minimal Inhibitory Concentration be used as an Infant Critical Care Regular Criteria?. <i>Current Pharmaceutical Biotechnology</i> , 2020, 21, 1052-1058.	0.9	0
4	Vancomycin Therapeutic Regime Adjustment in Newborns and Infants with Bacterial Infection: Case Series. <i>Current Pharmaceutical Biotechnology</i> , 2019, 20, 346-351.	0.9	3
5	CORRELATION BETWEEN PLASMA TAMOXIFEN CONCENTRATION AND TUMOR RESPONSE IN PATIENTS WITH BREAST CANCER: AT NEOADJUVANT TREATMENT WITH TAMOXIFEN. <i>International Journal of Pharmacy and Pharmaceutical Sciences</i> , 2017, 9, 100.	0.3	1
6	Albendazole-praziquantel interaction in healthy volunteers: kinetic disposition, metabolism and enantioselectivity. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 528-535.	1.1	35
7	Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 897-904.	1.1	14
8	Influence of Glomerular Filtration Rate on the Pharmacokinetics of Cyclophosphamide Enantiomers in Patients With Lupus Nephritis. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 965-972.	1.0	7
9	Determination of cyclophosphamide enantiomers in plasma by LC-MS/MS: Application to pharmacokinetics in breast cancer and lupus nephritis patients. <i>Chirality</i> , 2009, 21, 383-389.	1.3	8
10	Simultaneous determination of albendazole metabolites, praziquantel and its metabolite in plasma by high-performance liquid chromatography-electrospray mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2007, 44, 558-563.	1.4	38